NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $18.38 -0.05 (-0.27%) Closing price 07/9/2026 04:00 PM EasternExtended Trading$18.37 -0.01 (-0.05%) As of 07:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cullinan Therapeutics Stock (NASDAQ:CGEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cullinan Therapeutics alerts:Sign Up Key Stats Today's Range$18.08▼$18.7850-Day Range$12.05▼$18.4852-Week Range$5.68▼$19.43Volume448,130 shsAverage Volume1.23 million shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$32.00Consensus RatingModerate Buy Company Overview Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Read More Cullinan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreCGEM MarketRank™: Cullinan Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 411th out of 845 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingCullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCullinan Therapeutics has a consensus price target of $32.00, representing about 74.1% upside from its current price of $18.38.Amount of Analyst CoverageCullinan Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Cullinan Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cullinan Therapeutics are expected to grow in the coming year, from ($3.06) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.57% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 6.29.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 2.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.07 News SentimentCullinan Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cullinan Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for CGEM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $259,520.00 in company stock.Percentage Held by Insiders8.60% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Stock News HeadlinesCullinan Therapeutics (NASDAQ:CGEM) Insider Sells 8,000 SharesJuly 8 at 5:51 AM | insidertrades.comCullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset HopesJune 23, 2026 | finance.yahoo.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.July 10 at 1:00 AM | Porter & Company (Ad)Cullinan Therapeutics: Heading Toward PaydirtJune 11, 2026 | seekingalpha.comCullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases TranscriptJune 10, 2026 | seekingalpha.comCullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases - SlideshowJune 10, 2026 | seekingalpha.comCullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune DiseasesJune 10, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)June 10, 2026 | theglobeandmail.comSee More Headlines CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $10.35 at the beginning of 2026. Since then, CGEM stock has increased by 77.6% and is now trading at $18.38. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.09. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $232 million in an initial public offering on Friday, January 8th 2021. The company issued 11,900,000 shares at a price of $19.00-$20.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Top institutional investors of Cullinan Therapeutics include Assenagon Asset Management S.A. (0.10%). Insiders that own company stock include Lynx1 Capital Management Lp, Nadim Ahmed, Corrine Savill, Jennifer Michaelson, Jeffrey Alan Jones, Jacquelyn L Sumer, Mary Kay Fenton and Jeffrey Trigilio. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cullinan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings5/07/2026Today7/10/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CGEM's financial health is in the Green zone, according to TradeSmith. CGEM has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEM CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees30Year Founded2016Price Target and Rating Average Price Target for Cullinan Therapeutics$32.00 High Price Target$38.00 Low Price Target$26.00 Potential Upside/Downside+74.1%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$219.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.45% Return on Assets-47.64% Debt Debt-to-Equity RatioN/A Current Ratio10.28 Quick Ratio10.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book2.66Miscellaneous Outstanding Shares61,460,000Free Float56,173,000Market Cap$1.13 billion OptionableOptionable Beta-0.01 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CGEM) was last updated on 7/10/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...Profits Run | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...Eagle Publishing | SponsoredThe market’s crashing? … There’s an app for thatDuring the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...Weiss Ratings | SponsoredElon’s New Currency (BUY NOW)Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
